Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 48Recruiting 45Active not recruiting 30Terminated 23Unknown 5Not yet recruiting 5Withdrawn 4Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HER2-positive Advanced Breast Cancer 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Fluorodeoxyglucose F18 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × ribociclib × Clear all
NCT06481956 2024-07-01

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Zhejiang Cancer Hospital

Phase 2 Enrolling by invitation
40 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡